Ï㽶ÊÓƵ

Srinivas K. Tantravahi
( out of 137 reviews )

Srinivas K. Tantravahi, MBBS, MRCP(UK)

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City
801-585-2626

Sugar House Health Center

Salt Lake City
801-581-2000

  • Dr. Srinivas Tantravahi is an Associate Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the Huntsman Cancer Institute, Ï㽶ÊÓƵ of Utah. Board certified in Hematology and Medical Oncology, Dr. Tantravahi is an expert in the management of leukemias, myeloproliferative neoplasms, bone marrow failure, and genetic predisposition to related conditions.

    After completing his Internal Medicine residency and Hematology and Oncology fellowship training at the Ï㽶ÊÓƵ of Utah School of Medicine, Dr. Tantravahi joined the Ï㽶ÊÓƵ of Utah faculty in 2015. He actively engages in pioneering clinical trials, investigating innovative therapeutic strategies for myeloproliferative neoplasms, chronic myeloid leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Dr. Tantravahi is a member of American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.

    Dr. Tantravahi's clinical and research focus extends to the diagnosis and treatment of telomere biology disorders, with a particular emphasis on unraveling the genetic mechanisms underlying these disorders and various germline predispositions to bone marrow failure and leukemias.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Medical Council of India

    Patient Rating

    4.9 /5
    ( out of 137 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 23, 2024
    HUNTSMAN CANCER CENTER

    Dr. "T" made my visit easy, felt like it was friendly, professional and exceeded my expectations

    October 18, 2024
    HUNTSMAN CANCER CENTER

    He is a wonderful doctor, kind of patient

    October 16, 2024
    HUNTSMAN CANCER CENTER

    Dr. Tantravahi is simply the best.

    October 04, 2024
    HUNTSMAN CANCER CENTER

    Interpersonal interaction is fantastic. He treats me like a person, not a job. He listens and explains what the tests show and what to expect.

    July 12, 2024
    HUNTSMAN CANCER CENTER

    Dr. Tantravahi is an excellent physician. He has excellent skills and knowledge. He listened carefully to my concerns and answered my questions completely. He is a very pleasant person.

    July 07, 2024
    HUNTSMAN CANCER CENTER

    This was the best experience I have ever had with any doctor and I am 83.

    June 26, 2024
    HUNTSMAN CANCER CENTER

    Dr. T is one of the best doctor we have. He is always nice , knowledgeable and patient with us. We just love him.

    June 01, 2024
    HUNTSMAN CANCER CENTER

    Appreciated Dr. Tantravahi & Nate with their kind, unrushed , knowledgeable way of explaining my cancer. They carefully answered our questions on our level. Thankful to be under their care.

    May 26, 2024
    HUNTSMAN CANCER CENTER

    Dr Tantravahi is a very intelligent and caring doctor. He is always cheerful and friendly and explains the info on your chart so that you can understand it.

    See More Patient Comments

  • Dr. Srinivas Tantravahi is an Associate Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the Huntsman Cancer Institute, Ï㽶ÊÓƵ of Utah. Board certified in Hematology and Medical Oncology, Dr. Tantravahi is an expert in the management of leukemias, myeloproliferative neoplasms, bone marrow failure, and genetic predisposition to related conditions.

    After completing his Internal Medicine residency and Hematology and Oncology fellowship training at the Ï㽶ÊÓƵ of Utah School of Medicine, Dr. Tantravahi joined the Ï㽶ÊÓƵ of Utah faculty in 2015. He actively engages in pioneering clinical trials, investigating innovative therapeutic strategies for myeloproliferative neoplasms, chronic myeloid leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Dr. Tantravahi is a member of American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.

    Dr. Tantravahi's clinical and research focus extends to the diagnosis and treatment of telomere biology disorders, with a particular emphasis on unraveling the genetic mechanisms underlying these disorders and various germline predispositions to bone marrow failure and leukemias.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Medical Council of India

    Education history

    Fellowship Advanced Hematology & Oncology - Ï㽶ÊÓƵ of Utah Fellow
    Fellowship Hematology & Oncology - Ï㽶ÊÓƵ of Utah Fellow
    Residency Internal Medicine - Ï㽶ÊÓƵ of Utah Resident
    Residency Internal Medicine - Barnsley District General Hospital Senior House Officer
    Residency Internal Medicine - Sheffield Teaching Hospitals Senior House Officer
    Residency Internal Medicine - Rotherham District General Hospital Senior House Officer
    Residency Internal Medicine - George Elliot Hospital Senior House Officer
    Residency Internal Medicine - Macclesfield District General Hospital Senior House Officer
    Professional Medical Medicine - Guntur Medical College M.B.B.S.

    Selected Publications

    Journal Article

    1. Vardell VA, Ose J, Rets AV, Tantravahi SK, Patel AB (2024). Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis. Clin Lymphoma Myeloma Leuk. ()
    2. Babushok DV, DeZern AE, de Castro C, Rogers ZR, Beenhouwer D, Broder MS, Fanning S, Gibbs SN, Hanna R, Maciejewski JP, Scott BL, Tantravahi SK, Wlodarski MW, Yermilov I, Patel BJ (2024). Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia. Blood Adv. ()
    3. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. ()
    4. Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C (2022). Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol, 9(6), e434-e444. ()
    5. Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser KA, Miles RR, Beck DB, George T, Tantravahi SK (2021). A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv, 6(2), 405-409. ()
    6. Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD (2021). Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(11), 1277-1303. ()
    7. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, Pollyea DA, Radhakrishnan SM, Radhakrishnan S, Patel PA, Collins RH, Tantravahi SK, Deininger MW, Fan G, Druker BJ, Shinde U, Tyner JW, Press RD, McWeeney SK, Agarwal A (2021). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood, 139(8), 1208-1221. ()
    8. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. ()
    9. Kim K, McMillin GA, Bernard PS, Tantravahi S, Walker BS, Schmidt RL (2019). Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia. PLoS One, 14(12), e0226552. ()
    10. Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leuk Res, 87, 106262. ()
    11. Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, Ahmann JM, OHare T, Deininger MW (2019). The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv, 3(20), 2949-2961. ()
    12. Walker BS, Schmidt RL, Tantravahi S, Kim K, Hanson KE (2019). Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant. Transpl Infect Dis, 21(5), e13148. ()
    13. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, OHare T, Deininger MW (2018). Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res, 25(7), 2323-2335. ()
    14. Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9. ()
    15. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, OHare T, Deininger MW (2016). Age-related mutations and chronic myelomonocytic leukemia. Leukemia, 30(4), 906-13. ()
    16. Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7. ()
    17. Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, OHare T, Deininger MW (2015). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81. ()
    18. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2015). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-597. ()
    19. Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926. ()

    Book Chapter

    1. Tantravahi SK, Khorashad JS, Deininger MW (In Press). Genomic Landscape of myeloproliferative neoplasms. In Oxford Hand Book of Hematology.
    2. Tantravahi SK, Kovacsovics T (2015). Myeloma. In Randall RL (Ed.), Metastatic Bone Disease: An Integrated Approach to Patient Care (2016 Edition, pp. 83-102). New York: Springer.
    3. Kollepara SLS, Tantravahi SK, Batten J, Agarwal N (2014). Integrating emerging science into clinical practice: Targeting androgen signaling in Castration Resistant Metastatic Prostate Cancer. In Srivastava R, Maksymowicz W, Lopaczynski W (Eds.), Lost in Translation: Barriers in Incentives for Translational Research. Singapore: World Scientific Publishing Company.

    Letter

    1. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. [Letter to the editor]. Br J Haematol, 198(6), e78-e81. ()
    2. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia, 34(1), 317-321. ()
    3. Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (2016). A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. [Letter to the editor]. Leuk Lymphoma, 57(10), 2441-4. ()

  • Clinical Trials